Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.72 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480862 | 0.84 | HTR6 (1.00) | HTR6BRD4ALDH1A1HTR2B | |
| Water SCHEMBL4559431 | 0.83 | HTR6 (0.98) | HTR6BRD4ALDH1A1HTR2B | |
| Water SCHEMBL4559433 | 0.83 | HTR6 (0.98) | HTR6BRD4ALDH1A1HTR2B | |
| SCHEMBL4477508 | 0.80 | HTR6 (0.80) | HTR6BRD4ALDH1A1HTTPTPN2 | |
| SCHEMBL6475723 | 0.80 | HTR6 (0.80) | HTR6BRD4ALDH1A1PGR | |
| SCHEMBL6476010 | 0.79 | HTR6 (0.81) | HTR6BRD4 | |
| SCHEMBL4482936 | 0.79 | HTR6 (0.81) | HTR6 | |
| SCHEMBL6472087 | 0.78 | HTR6 (0.76) | HTR6PTPN2PTPN1PTPN5TSHR | |
| SCHEMBL4487505 | 0.76 | HTR6 (0.68) | HTR6ALDH1A1HTTPTPN2PTPN1 | |
| SCHEMBL16551332 | 0.71 | HTR6 (0.48) | HTR6GHSRALDH1A1HTTPFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| US-7534801-B2 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-05-19 | — | — | US | claimed |
| US-20050107431-A1 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-05-19 | — | — | US | claimed |
| WO-2005037830-A1 | PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-04-28 | — | — | WO | claimed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-7534801-B2 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| US-20050107431-A1 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005037830-A1 | PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885BRD4 1671/4885TYMS 612/4885 |
| US-20050107431-A1 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | HTR6 1/4885BRD4 1830/4885TYMS 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.